In this regard, GC-C has emerged as an attractive candidate for CAR-T cell therapy in colorectal cancer for the following reasons: first, the broad selectivity of GC-C expression in the human intestine; second, expression on the cell surface; and finally, the ability to maintain expression in colorectal cancers at both primary and metastatic sites (99). The gene discussed is GUCY2C; the disease is colorectal cancer.